In patients with osteosarcoma, the levels of ANGPTL2, which promotes lung PMN formation, were systemically elevated relative to healthy subjects, thus offering the possibility for intervention to hinder ANGPTL2-mediated signaling and subsequent pro-metastatic effects (213). Here, ANGPTL2 is linked to osteosarcoma.